New imaging study tracks cancer Drug's path in Hard-to-Treat tumors
NCT ID NCT05963867
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 31 times
Summary
This study is for adults with advanced small cell lung cancer or other neuroendocrine cancers that haven't responded to standard treatments. Researchers want to see how the experimental drug BI 764532 moves through the body and gets absorbed by tumors using special PET scans. About 12 participants will receive the drug and undergo imaging to track its distribution, with regular check-ups to monitor safety and any benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC Locatie VUMC
RECRUITINGAmsterdam, 1081HV, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.